ArticleKidney international reports2025
Community-Acquired Acute Kidney Injury and Late Kidney Dysfunction in Survivors of COVID-19 Hospitalization.
Article in Kidney international reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Data on the incidence and risk factors for renal long COVID are scarce. We aimed to investigate 2 acute kidney injury (AKI) phenotypes, namely community-acquired (CA; CA-AKI) and hospital-acquired (HA; HA-AKI), and the development of late kidney dysfunction in survivors of COVID-19 hospitalization. Methods: This is a prospective cohort study of survivors of moderate-to-severe COVID-19 hospitalization in Brazil, from March to August 2020. The patients were assessed for up to 11 months after hospital discharge. Exposure was CA-AKI and HA-AKI. The main outcome was kidney dysfunction defined as incident low estimated glomerular filtration rate (eGFR; < 60 ml/min per 1.73 m Results: A total of 655 survivors were evaluated (6.5 ± 1.9 follow-up months); 79% had AKI (35% CA and 43% HA); 14% used kidney replacement therapy (KRT). Late kidney dysfunction occurred in 28% of the patients (16% with incident low eGFR and 27% with eGFR decline ≥ 25%). CA-AKI, but not HA-AKI, was independently associated with late kidney dysfunction (adjusted odds ratio [aOR] = 7.3, 95% confidence interval (CI): 3.6-15.8 and aOR = 2.2, 95% CI: 0.9-4.8, respectively). Conclusion: In conclusion, late kidney dysfunction affected 1 in 4 COVID-19 survivors. CA-AKI, but not HA-AKI, was an independent risk factor for late kidney dysfunction. These findings suggest that renal long COVID might be frequent and that a specific AKI phenotype (CA-AKI) may play a crucial role in its development. Our research highlights the need for CA-AKI prevention and for the long-term follow-up and care of patients affected by this AKI phenotype during COVID-19 infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.